Yiwen Chen

Superconducting 2D cuprate with a single CuO2 plane

Hengsheng Luo, Dongjoon Song, Yijun Yu, Liguo Ma et autres

cn, ca, il (code pays fourni par la source)

The role of surgical resection, locoregional liver-directed treatments, and continuous systemic treatment in patients with liver metastatic pancreatic cancers

X. Li, Guoliang Qiao, Yiwen Chen, Fan Gao et autres

BACKGROUND: No consistent clinical criteria and multimodal approaches to manage liver metastatic pancreatic cancer patients after effective systemic treatment have been developed. This study aims to assess the efficacy of surgical resection, liver-directed local therapy, or continuous systemic treatment in liver metastatic …

cn (code pays fourni par la source)

Publisher Correction: Oncolytic virus VG161 in refractory hepatocellular carcinoma

Yinan Shen, Xueli Bai, Qi Zhang, Xingmei Liang et autres

cn, ca (code pays fourni par la source)

Oncolytic virus VG161 in refractory hepatocellular carcinoma

Yinan Shen, Xueli Bai, Qi Zhang, Xingmei Liang et autres

cn, ca (code pays fourni par la source)

Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection.

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

571 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy in hepatocellular carcinoma (HCC). Among BCLC A/B patients (pts) with MVI, adjuvant transarterial chemoembolization has been reported to provide a 1-year recurrence-free survival (RFS) rate of …

cn (code pays fourni par la source)

Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial

Tao Ma, Xueli Bai, Qi Zhang, Wen Chen et autres

BACKGROUND AND AIMS: The role of adjuvant transarterial chemoembolization (TACE) for HCC following curative resection remains controversial. We aimed to determine the effectiveness of postoperative adjuvant TACE in patients with HCC​​​​​. APPROACH AND RESULTS: In this randomized phase 3 trial, histologically confirmed …

cn (code pays fourni par la source)

Systemic Treatment Followed by Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced Pancreatic Cancer

Guoliang Qiao, Xueli Bai, Xiang Li, Qi Zhang et autres

OBJECTIVE: To assess the efficacy of this approach and establish the criteria that identify patients with locally advanced pancreatic cancer (LAPC) who may achieve survival benefits from radical resection combined with intestinal autotransplantation (RRCIA). BACKGROUND: Surgical resection for LAPC remains challenging and …

cn, us (code pays fourni par la source)

Novel Oncolytic Virus VG161 in Hepatocellular Carcinoma Patients Refractory to Standard Systemic Therapies

Tingbo Liang, Yinan Shen, Xueli Bai, Qi Zhang et autres

cn, ca (code pays fourni par la source)

Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.

Xueli Bai, Yiwen Chen, Junlei Zhang, Wendi Hu et autres

4108 Background: TACE-based conversion therapies are warranted for over 70% of patients with intermediate-advanced unresectable hepatocellular carcinoma (uHCC). This study aimed to investigate the efficacy and safety of envafolimab plus lenvatinib and TACE as conversion therapy in uHCC. Methods: This is an …

cn (code pays fourni par la source)

Adjuvant therapy with donafenib plus anti–PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study).

Yiwen Chen, Yan Shen, Min Zhang, Jian Wu et autres

e16228 Background: There is no universally accepted standard treatment option or strategy for post-surgery adjuvant therapy for HCC. Among BCLC A/B patients with MVI, adjuvant TACE provided a 1-year recurrence-free survival rate (RFSR) of around 60-70%. We conducted a pilot study to …

cn (code pays fourni par la source)

Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial

Chengxiang Guo, Junlei Zhang, Xin Huang, Yiwen Chen et autres

BACKGROUND AND AIMS: Many patients with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A exceeding the Milan criteria, or of BCLC stage B, can undergo resection after successful preoperative therapy, but an optimal approach has not been identified. We investigated preoperative …

cn (code pays fourni par la source)